{
    "clinical_study": {
        "@rank": "43463", 
        "acronym": "Hp-in-CF", 
        "arm_group": {
            "arm_group_label": "Cystic Fibrosis Patients", 
            "description": "Patients with Cystic Fibrosis with two known severe (class I and class II) mutations"
        }, 
        "biospec_descr": {
            "textblock": "Peripheral blood serum"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Cystic Fibrosis is a genetic disease with variable severity, and a predisposition for lung\n      infection. Usually severity is determined by the class of CF mutations, but even among\n      patients with the same severity of mutations there is a variation of the severity of CF.\n\n      Haptoglobin has several types (phenotypes), one of them was found to be related to\n      infectious complications.\n\n      In this study the investigators aim to find a correlation between Haptoglobin phenotypes in\n      patients with CF and frequency of infectious complications.\n\n      To this end the investigators will collect serum from CF patients, and determine their\n      Haptoglobin protein phenotype. The investigators will correlate Haptoglobin phenotype to\n      retrospectively gathered data on infectious complications."
        }, 
        "brief_title": "Correlation Between Haptoglobin Phenotypes and Infectious and Other Complications in Cystic Fibrosis Patients", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Cystic Fibrosis is a genetic disease with variable severity, and a predisposition for lung\n      infection. The severity of the disease is determined by genetic factors (type of mutation),\n      environmental factors (exposure to bacteria) and behavioral (adherence with therapy). Even\n      among patients with the same severity of mutations there is a variation of the severity of\n      CF.\n\n      Haptoglobin is a protein responsible for collecting Iron from senescent Red Blood Cells.\n      There are two genes of Haptoglobin, numbered 1 and 2, and combinations between the two genes\n      create three forms of proteins: 1-1, 1-2, and 2-2. The 1-1 Phenotype was found to be\n      associated with a predisposition to infection.\n\n      In this study the investigators aim to find a correlation between Haptoglobin phenotypes in\n      patients with CF and frequency of infectious complications.\n\n      To this end the investigators will collect serum from CF patients, and determine their\n      Haptoglobin protein phenotype by gel- electrophoresis. The investigators will correlate\n      Haptoglobin phenotype to retrospectively gathered data on infectious complications."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients diagnosed with CF according to diagnostic criteria , between the ages of 0 and\n        50, who are themselves, or their parents or guardians, able to give informed consent.\n\n        Two known severe (class I or class II) mutations\n\n        Exclusion Criteria:\n\n        none"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients diagnosed with CF"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01806025", 
            "org_study_id": "CMC-12-0093-CTIL"
        }, 
        "intervention": {
            "arm_group_label": "Cystic Fibrosis Patients", 
            "intervention_name": "no intervention", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cystic Fibrosis", 
            "Haptoglobin"
        ], 
        "lastchanged_date": "April 7, 2013", 
        "number_of_groups": "1", 
        "official_title": "Correlation Between Haptoglobin Phenotypes and Infectious and Other Complications in Cystic Fibrosis Patients", 
        "other_outcome": {
            "description": "Haptoglobin phenotype in serum will be determined by gel electrophoresis", 
            "measure": "Haptoglobin phenotype", 
            "safety_issue": "No", 
            "time_frame": "one visit"
        }, 
        "overall_contact": {
            "email": "michal.shteinberg@gmail.com", 
            "last_name": "Michal Shteinberg, MD", 
            "phone": "972-50-6265846"
        }, 
        "overall_contact_backup": {
            "email": "miyora@012.net.il", 
            "last_name": "Michal Gur, MD", 
            "phone": "972-4-8250517"
        }, 
        "overall_official": {
            "affiliation": "Pulmonology Institute and CF Center, Carmel Medical Center", 
            "last_name": "Michal Shteinberg, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Lung function as determined by spirometry FEV1 (% expected), normalized by age", 
            "measure": "FEV1", 
            "safety_issue": "No", 
            "time_frame": "best in last 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01806025"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Carmel Medical Center", 
            "investigator_full_name": "Michal Steinberg", 
            "investigator_title": "Pulmonology Consultant", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "number of courses of antibiotics the patient received in the last year", 
                "measure": "No. of antibiotic courses per year of follow up", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "number of days the patient received antibiotics", 
                "measure": "No. of days with antibiotics per year of follow up", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }
        ], 
        "source": "Carmel Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Carmel Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}